Tuesday, January 13, 2004 1:06:53 PM
Also, the type of deal that CMIH was after was money up front for the R&D ($250,000 or thereabouts) plus royalties (to DNAP) from any eventual products. This was part of DNAP's now defunct partner early, partner often philosophy. It was in essence, a no-risk proposition from DNAP's standpoint. Were DNAP to go this route they would have no need for Jolla Cove.
So how does DNAP acquire a drug pipeline that will someday be worth something yet does not cost more than they can afford???? Got me. I dunno.
Unitronix Corp. to Invest $3 Million in USA Unity Coin Project • UTRX • Oct 7, 2024 7:08 AM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM